Business Description
AC Immune SA
NAICS : 325412
SIC : 2834
ISIN : CH0329023102
Description
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.22 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.51 | |||||
| Beneish M-Score | 42777.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.8 | |||||
| 3-Year EBITDA Growth Rate | 8.9 | |||||
| 3-Year EPS without NRI Growth Rate | 6.7 | |||||
| 3-Year FCF Growth Rate | 4.4 | |||||
| 3-Year Book Growth Rate | -17.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 74.11 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.25 | |||||
| 9-Day RSI | 44.01 | |||||
| 14-Day RSI | 44.65 | |||||
| 6-1 Month Momentum % | 36.55 | |||||
| 12-1 Month Momentum % | 6.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.86 | |||||
| Cash Ratio | 1.56 | |||||
| Days Sales Outstanding | 175.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.3 | |||||
| Shareholder Yield % | -0.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -86.63 | |||||
| Net Margin % | -92.89 | |||||
| FCF Margin % | 101.28 | |||||
| ROE % | -28.56 | |||||
| ROA % | -20.02 | |||||
| ROIC % | -38.65 | |||||
| 3-Year ROIIC % | 10.08 | |||||
| ROC (Joel Greenblatt) % | -488.28 | |||||
| ROCE % | -26.55 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 9.61 | |||||
| PS Ratio | 6.32 | |||||
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 3.22 | |||||
| Price-to-Free-Cash-Flow | 7.16 | |||||
| Price-to-Operating-Cash-Flow | 7.05 | |||||
| EV-to-EBIT | -2.88 | |||||
| EV-to-Forward-EBIT | 3.07 | |||||
| EV-to-EBITDA | -3.04 | |||||
| EV-to-Revenue | 2.66 | |||||
| EV-to-Forward-Revenue | 0.84 | |||||
| EV-to-FCF | 2.95 | |||||
| Price-to-Net-Current-Asset-Value | 3.46 | |||||
| Price-to-Net-Cash | 5.88 | |||||
| Earnings Yield (Greenblatt) % | -34.76 | |||||
| FCF Yield % | 15.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AC Immune SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 43.511 | ||
| EPS (TTM) (€) | -0.425 | ||
| Beta | 0.91 | ||
| Volatility % | 128.43 | ||
| 14-Day RSI | 44.65 | ||
| 14-Day ATR (€) | 0.129502 | ||
| 20-Day SMA (€) | 2.802 | ||
| 12-1 Month Momentum % | 6.26 | ||
| 52-Week Range (€) | 2.06 - 4.785 | ||
| Shares Outstanding (Mil) | 98.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AC Immune SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AC Immune SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
AC Immune SA Frequently Asked Questions
What is AC Immune SA(STU:IMR)'s stock price today?
The current price of STU:IMR is €2.77. The 52 week high of STU:IMR is €4.79 and 52 week low is €2.06.
When is next earnings date of AC Immune SA(STU:IMR)?
The next earnings date of AC Immune SA(STU:IMR) is 2025-02-06 Est..
Does AC Immune SA(STU:IMR) pay dividends? If so, how much?
AC Immune SA(STU:IMR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers